miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival
miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival
复制标题
miR-182 作为神经胶质瘤进展和患者生存的预后标志物
DOI：
10.2353/ajpath.2010.090812
复制
发表时间：
2010-07-01
影响因子：
6
通讯作者：
Li, Jun
中科院分区：
文献类型：
--
作者：
Jiang, Lili;Mao, Pu;Li, Jun
越来越多的证据表明，miRNA表达可用作人类癌症的诊断和预后标志物。我们报道了miR-182在胶质瘤细胞系和人类原发性胶质瘤标本中的表达水平显著上调。定量PCR分析显示，与从同一患者获得的相邻非肿瘤脑组织相比，胶质瘤肿瘤中的miR 182显著增加高达32倍。在253例（98%）存档的人脑胶质瘤活检标本中，通过原位杂交进一步鉴定了miR-182的表达升高。统计学分析显示miR-182表达与世界卫生组织胶质瘤分级显著相关（P < 0.001）。脑胶质瘤患者5年累积生存率为51.54%（95%可信区间，0.435 - 0.596），而在低miR-182表达组中，（95%置信区间，0.027至0.118）多因素考克斯回归分析显示，miR-182表达是胶质瘤患者生存的独立预后指标。实时荧光定量RT-PCR分析进一步验证了原位杂交分析中miR-182表达水平与胶质瘤临床特征的相关性。综上所述，我们的研究结果表明，miR-182可能是胶质瘤进展的一个有价值的标志物，并且miR-182高表达与恶性胶质瘤患者的总体生存率低相关。(Am J Pathol 2010，177：29-38 DOI：10.2353/ajpath.2010.090812）
Accumulating evidence indicates that miRNA expression can be used as a diagnostic and prognostic marker for human cancers. We report that the expression level of miR-182 was markedly up-regulated in glioma cell lines and in human primary glioma specimens. Quantitative PCR analysis showed that miR182 was significantly increased by up to 32-fold in glioma tumors compared with the adjacent nontumor brain tissues obtained from the same patient. Elevated expression of miR-182 was further identified by in situ hybridization in 248 of 253 (98%) archived human glioma biopsies tested. Statistical analysis revealed a significant correlation between miR-182 expression and World Health Organization glioma grading (P < 0.001). The cumulative 5-year survival rate of glioma patients was 51.54% (95% confidence interval, 0.435 to 0.596) in the low miR-182-expression group, whereas it was only 7.23% (95% confidence interval, 0.027 to 0.118) in the high miR-182-expression group (P = 0.001), and multivariate Cox regression analysis indicated that miR-182 expression was an independent prognostic indicator for the survival of glioma patients. Moreover, the correlations of miR-182 level with the clinical features of glioma suggested in the in situ hybridization analysis were further verified by the real-time RT-PCR analysis. Taken together, our results suggest that miR-182 could be a valuable marker of glioma progression and that high miR-182 expression is associated with poor overall survival in patients with malignant glioma. (Am J Pathol 2010, 177:29-38 DOI: 10.2353/ajpath.2010.090812)